A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma

* Male or female who has received a single dose of HUMIRA prior to a confirmed diagnosis of HSTCL. * Confirmed diagnosis of CD or UC as documented by a Gastroenterologist or physician who diagnosed the CD or UC. * Confirmed diagnosis of HSTCL as determined by a biopsy performed on a specimen taken from the patient. * Patients 18 years old and older must voluntarily sign and date an IRB/EC approved Informed Consent Form. For patients younger than 18 years old, a parent or legal guardian is required to voluntarily sign and date an IRB/EC approved Informed Consent Form. Pediatric patients will be included in all discussions if possible, in order to obtain their assent.

* Male or female who has not received at least a single dose of adalimumab prior to a confirmed diagnosis of HSTCL. * Unconfirmed diagnosis of HSTCL, CD or UC, respectively. * The patient or the patient's HCP is unwilling to participate in this study. * The parents or legal guardians (in the case of patients younger than 18 years of age), who are unable and/or unwilling to consent to the patient's participation in this study.